Additionally, the expressions of ITGB2, RAC2, ITGAM, and CXCL10 were significantly correlated with a good prognosis in TNBC and may be potential therapeutic targets for the development of gene therapies for TNBC patients with NAFLD. This evidence concerns the gene CXCL10 and metabolic dysfunction-associated steatotic liver disease.